USA flag logo/image

An Official Website of the United States Government

L1 mutagenesis for mammalian models of human diseases

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75600
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
RR021289
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
535 West Second Street Suite 10 Lexington, KY 40508
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: L1 mutagenesis for mammalian models of human diseases
Agency: HHS
Contract: 1R43RR021289-01
Award Amount: $99,724.00
 

Abstract:

DESCRIPTION (provided by applicant): Transposagen is developing an innovative mammalian random mutagenesis system that uses an L1 retrotransposon for direct germ-line mutagenesis. Transposagen's goal is to produce "mutator rats". In these rats, mutagensis will occur in sperm and some offspring will contain single gene disruptions. We will use the mouse to optimize and validate our system because of the much higher cost in producing transgenic rats. We have developed "mutator mice" containing a marked L1 transgene capable of germ-line insertional mutagenesis. The focus of this proposal is to validate the Transposagen random mutagenesis system as a tool for functional genomics. Phase I of this project includes characterization of the mutator mice. Specific aim 1 is to determine the frequency of insertional mutagenesis in the sperm of mutator mice. Specific aim 2 is to determine the percentage of insertions that insert into genes. Specific aim 3 is to determine the efficiency of gene disruption. Phase II of the project will use the information gained from the Phase I mouse studies to create mutator rats. L1 elements are present in all mammals and a human L1 element is capable of high-level retrotransposition in human, mouse, hamster, feline, and even quail cells. Therefore, our findings in mice from this study should extrapolate directly to rats. Transposagen's random mutagenesis system could utlimately be adapted for use in any mammal. Mutator mice and rats will substantially aid drug discovery programs by producing animal models for new drug targets.

Principal Investigator:

Eric M. Ostertag
2672591086
OSTERTAG@MAIL.MED.UPENN.EDU

Business Contact:


2672591086
Small Business Information at Submission:

Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. 3160 Chestnut St, Ste 200 Philadelphia, PA 19104

EIN/Tax ID: 861092980
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No